Clinical Efficacy of Ovateleaf Holly Bark Decoction Combined with DP Chemotherapy Regimen in Treating Advanced Non-small Cell Lung Cancer

LIN Cai-zhi; HU Nai-qiang; ZHAO Hai-yan; LIAO Dan; SHAO Wen-hui; HAN Dan

doi:10.13422/j.cnki.syfjx.2017150184

您当前的位置：

首页 >

文章列表页 >

Clinical Efficacy of Ovateleaf Holly Bark Decoction Combined with DP Chemotherapy Regimen in Treating Advanced Non-small Cell Lung Cancer

更新时间：2024-01-04

- Clinical Efficacy of Ovateleaf Holly Bark Decoction Combined with DP Chemotherapy Regimen in Treating Advanced Non-small Cell Lung Cancer
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 23, Issue 15, Pages: 184-190(2017)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2017150184
  CLC： R734.2
- Published：2017
- 稿件说明：
移动端阅览
LIN Cai-zhi, HU Nai-qiang, ZHAO Hai-yan, et al. Clinical Efficacy of Ovateleaf Holly Bark Decoction Combined with DP Chemotherapy Regimen in Treating Advanced Non-small Cell Lung Cancer[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(15): 184-190.
DOI：

LIN Cai-zhi, HU Nai-qiang, ZHAO Hai-yan, et al. Clinical Efficacy of Ovateleaf Holly Bark Decoction Combined with DP Chemotherapy Regimen in Treating Advanced Non-small Cell Lung Cancer[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(15): 184-190. DOI： 10.13422/j.cnki.syfjx.2017150184.

摘要

目的：综合评价救必应汤联合DP化疗方案[多西他赛（docetaxel）+顺铂（cisplatin）]治疗晚期非小细胞肺癌的临床疗效。方法：选取确诊的晚期（Ⅲb~Ⅳ）非小细胞肺癌（NSCLC）患者120例，随机分为两组，各60例，治疗组采用救必应汤联合DP化疗方案，对照组仅采用DP化疗方案。比较两组患者近期临床疗效、免疫情况、生活质量、生存情况及毒副反应。结果：近期临床疗效，治疗组总有效率和疾病控制率均优于对照组，尤其是疾病控制率方面更优（P< 0.05）。免疫功能，治疗组中的CD3+，CD4+，CD4+/CD8+水平明显高于治疗前及对照组（P< 0.01）；两组患者白细胞介素-2受体（SIL-2R），白细胞介素-6（IL-6），肿瘤坏死因子-α（TNF-α）水平均下降（P< 0.01）。生活质量，治疗后治疗组在肺癌特异情况、社会（家庭）作用及总评分方面优于对照组（P< 0.05，P< 0.01）。生存情况，治疗组平均无进展生存期（PFS）（4.45月）高于对照组（3.40月），1年生存率治疗组（56.67%）高于对照组（30.00%）（P< 0.05）。毒副反应，治疗组在Ⅲ~Ⅳ度骨髓、胃肠道反应及周围神经毒性方面优于对照组（P< 0.05）。结论：救必应汤联合DP方案可以提高晚期NSCLC患者的临床有效率及免疫功能，改善患者的生活质量，延长患者的生存时间，降低化疗的毒副反应。

Abstract

Objective: To investigate the clinical efficacy of Ovateleaf Holly Bark decoction combined with DP chemotherapy (docetaxel+cisplatin) in treatment of advanced (Ⅲb-Ⅳ) non-small cell lung cancer. Method: A total of 120 patients with advanced non-small cell lung cancer (NSCLC) were randomly divided into two groups. The treatment group (60 cases) was given Ovateleaf Holly Bark decoction combined with DP chemotherapy regimen

while the control group (60 cases) received chemotherapy alone. Clinical efficacy

immune function

quality of life

survival and adverse reactions were compared between two groups. Result: In terms of the short-term clinical efficacy

the total effective rate and the disease control rate of treatment group were better than those of control group

especially in the disease control rate (P<0.05). Regarding the immune function

levels of CD3+

CD4+

CD4+/CD8+ in treatment group were significantly higher than those in control group (P<0.01). Two groups showed decreases in serum interleukin-2 receptor (SIL-2R)

interleukin-6 (IL-6)

tumor necrosis factor-alpha (TNF-α) levels (P< 0.01). As for the quality of life

after treatment

specific situations of lung cancer

social(family) functions and total score of the treatment group were better than those of control group (P<0.05

P< 0.01). With respect to the survival

the mean progression free survival(PFS)(4.45 months) in treatment group was higher than that in control group (3.40 months). The one-year survival rate of treatment group (56.67%) was higher than that of control group (30.00% )(P< 0.05). In terms of the adverse reaction

the treatment group was superior to control group in the Ⅲ-Ⅳ degree of bone marrow

gastrointestinal reactions and peripheral nerve toxicity

with statistically significant differences (P<0.05). Conclusion: Ovateleaf Holly Bark decoction combined with DP regimen can improve the clinical efficiency and the immune function of patients with advanced NSCLC

improve their quality of life

prolong their survival time and reduce the adverse reactions of chemotherapy.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Buzhong Yiqitang Regulates Endoplasmic Reticulum Stress to Attenuate Cisplatin Resistance in Non-small Cell Lung Cancer via Nrf2/ROS Pathway

Buzhong Yiqitang Regulates Endoplasmic Reticulum Stress via Nrf2/ROS/PERK/CHOP Signaling Pathway to Attenuate Cisplatin Resistance in NSCLC

Buzhong Yiqitang Regulates Apoptosis via Nrf2/ROS Pathway to Alleviate Cisplatin Resistance in A549/DDP Cells

Mechanism of PI3K/Akt/mTOR Signaling Pathway Against Non-small Cell Lung Cancer and Chinese Medicine Intervention： A Review

Mechanism of Stemona tuberosa Alkaloids in Inhibiting Proliferation and Inducing Apoptosis of Non-small Cell Lung Cancer NCI-H460 Cells

Related Author

YU Dan

MU Qirui

LI He

LIU Yuetong

HUANG Jingyi

GAO Yuan

LI He

LIU Yuetong

Related Institution

College of Integrated Chinese and Western Medicine， Liaoning University of Traditional Chinese Medicine

College of Integrated Traditional Chinese and Western Medicine， Liaoning University of Traditional Chinese Medicine

College of Integrative Chinese and Western Medicine， Liaoning University of Traditional Chinese Medicine

Gansu Provincial Hospital of Traditional Chinese Medicine

Gansu University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰